Brillia Health Cough Control

Lapine Bradykinin Immune Globulin (12c, 30c, 50c), Lapine Morphine Immune Globulin (12c, 30c, 50c), Lapine Histamine Immune Globulin (12c, 30c, 50c)


Hadaf Llc
Human Otc Drug
NDC 72123-007
Brillia Health Cough Control also known as Lapine Bradykinin Immune Globulin (12c, 30c, 50c), Lapine Morphine Immune Globulin (12c, 30c, 50c), Lapine Histamine Immune Globulin (12c, 30c, 50c) is a human otc drug labeled by 'Hadaf Llc'. National Drug Code (NDC) number for Brillia Health Cough Control is 72123-007. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Brillia Health Cough Control drug includes Lapine Bradykinin Immune Globulin - 12 [hp_C]/1 Lapine Histamine Immune Globulin - 12 [hp_C]/1 Lapine Morphine Immune Globulin - 12 [hp_C]/1 . The currest status of Brillia Health Cough Control drug is Active.

Drug Information:

Drug NDC: 72123-007
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Brillia Health Cough Control
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lapine Bradykinin Immune Globulin (12c, 30c, 50c), Lapine Morphine Immune Globulin (12c, 30c, 50c), Lapine Histamine Immune Globulin (12c, 30c, 50c)
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Hadaf Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LAPINE BRADYKININ IMMUNE GLOBULIN - 12 [hp_C]/1
LAPINE HISTAMINE IMMUNE GLOBULIN - 12 [hp_C]/1
LAPINE MORPHINE IMMUNE GLOBULIN - 12 [hp_C]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 31 Jul, 2020
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 14 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Hadaf LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:FX59DZ02OS
7U4T47R0DD
OS064NQ92E
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
72123-007-012 BLISTER PACK in 1 BOX (72123-007-01) / 10 TABLET in 1 BLISTER PACK31 Jul, 2020N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose homeopathic, reduces frequency and intensity of cough reduces pain responselapine histamine immune reduces histamine and inflammation response

Product Elements:

Brillia health cough control lapine bradykinin immune globulin (12c, 30c, 50c), lapine morphine immune globulin (12c, 30c, 50c), lapine histamine immune globulin (12c, 30c, 50c) magnesium stearate microcrystalline cellulose isomalt anhydrous citric acid aspartame saccharin sodium lapine morphine immune globulin lapine morphine immune globulin lapine bradykinin immune globulin lapine bradykinin immune globulin lapine histamine immune globulin lapine histamine immune globulin

Indications and Usage:

Uses • suppresses wet and dry cough • reduces severity and duration of symptoms, including nasal congestion, cough and sore/itchy throat • antihistamine and decongestant/anti-inflammatory • reduces sore throat pain

Warnings:

Warnings stop use and ask a doctor if symptoms persist or worsen. if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away. allergic (hypersensitivity) reactions may occur in very rare cases. do not use if known sensitivity to brillia health cough control or any of its ingredients exists.

Do Not Use:

Warnings stop use and ask a doctor if symptoms persist or worsen. if pregnant or breast-feeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away. allergic (hypersensitivity) reactions may occur in very rare cases. do not use if known sensitivity to brillia health cough control or any of its ingredients exists.

Dosage and Administration:

Directions • for adults and children 3 years and older. • take orally by holding tablet in the mouth until completely dissolved, without food. • 1 to 2 tablets 3 times daily. for severe symptoms, take 4 to 6 times daily for the first 3 days.

Stop Use:

Stop use stop use and ask a doctor if symptoms persist or worsen.

Package Label Principal Display Panel:

20 tablets ndc: 72123-007-01 label 1


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.